Report
BioNTech SE : Greater COMIRNATY opportunity + expanding oncology pipeline
>Lifting our 2021 sales forecast from € 13.15bn to € 19.63bn - FY guidance also looks too low in our view. It stands at c. € 15.9bn in revenues (based on a fixed order book of c. 2.2bn doses as of July 2021) and planned operating expenses of € 1.2bn to € 1.35bn. There is no guidance out on gross profit, EBIT or EPS. The deal with Pfizer is a 50:50 profit-sharing agreement (each company sells in predefined territories; profit-sharing at the gross profit level; 75% gro...
Underlying
BioNTech SE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Martial Descoutures
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.